Integrating Targeted Therapies into HMA-Venetoclax in AML: Perspectives from ASCO 2026

15 Posts Not To Miss From ASCO 2026: GU Edition

15 Posts Not To Miss From ASCO 2026: GI Edition

Muna Al-Khaifi: Redefining Survivorship Care - Key Lessons from ASCO 2026

Bridging the Gap Between Clinical Practice and Holistic, Patient-Centred Care - ESO

Oncology News, Insights, Stories by OncoDaily

OncoDaily Party 2026: Chicago Lights
OncoDaily Pulse

OncoDaily Party 2026: Chicago Lights

20 Posts Not To Miss From ASCO 2026: Lung Edition
Not To Miss

20 Posts Not To Miss From ASCO 2026: Lung Edition

Erika Ruiz-Garcia
Voices

Erika Ruiz-Garcia: Who Makes the Magic Happen Behind the Scenes at ASCO 2026? 

Celebrating the Unbreakable Spirit of Survivors - National Cancer Survivors Day

10 Must-Read Posts in Radiotherapy This Week: Week June 1 - June 7

Alejandra Mendez: An Urgent Call to Guarantee Humanitarian Corridors for Children With Cancer

Chemoimmunotherapy May Improve Survival Over PD-(L)1 Monotherapy in PD-L1–High Advanced NSCLC

NEMIO Updates: Neoadjuvant ddMVAC Plus Durvalumab ± Tremelimumab in Muscle-Invasive Bladder Cancer

Carboplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Cancer

OncoDaily Ambassadors at ASCO 2026

Voices
Christian Rolfo, Humaid Al-Shamsi

Christian Rolfo: Delighted to host Prof. Al Shamsi for Our Distinguished Lecture Today

Fidel Rubagumya: Survival Outcomes of Cervical Cancer Patients Treated With EBRT Boost in Rwanda

Shanda Blackmon: It is an Honor to Stand Beside Chris Malasrie and Danny Chu

Nickalus Khan: One of the Highlights of This Year Has Been Working With Eva Wu

Estela Rodriguez: Packed Room at the Sylvester Annual Retreat

Naveen Pemmaraju: Wonderful Evening Together for Our Annual Leukemia Fellow Graduation

Wafik S. El-Deiry: What a Lovely Surprise to Find That the Person Sitting Next to Me is Jenny Grandis

FDA Approvals
Decnupaz

FDA Approved Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN

FDA Approves FoundationOne CDx as Companion Diagnostic for TEPMETKO in METex14 NSCLC

FDA approved Atezolizumab for adjuvant treatment of MDR–positive MIBC

FDA Grants Approval for Oral Decitabine/Cedazuridine With Venetoclax in Newly Diagnosed AML

FDA Greenlit New Pancreatic Cancer Drug Daraxonrasib For Expanded Access

FDA Grants Full Approval of Tecartus for Relapsed/Refractory Mantle Cell Lymphoma in Adults

FDA Grants Fast Track Designation to TRI-611 in ALK-Positive NSCLC

OncoDaily 100
100 Xfluencers in Prostate Cancer

100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2025

The 100 Most Influential CEOs in Oncology in 2025 (Full List)

The 100 Most Influential People in Oncology in 2025 (Full List)

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

Celebrities and Cancer

OncoCalendar

35th Annual Mayo Clinic Hematology/Oncology Reviews 2026

Mayo Clinic

30 Jul
Mayo Clinic

Mayo Clinic Oncology Review 2026

Mayo Clinic

18 Jul
Mayo Clinic

Mayo Clinic Genito-Urinary Oncology Summit 2026

Mayo Clinic

16 Jul
Genito-Urinary Oncology

Mayo Clinic - Updates in Hematology and Oncology: Global Perspectives 2026

Mayo Clinic

26 Jun
Mayo Clinic

NCCN Academy for Excellence And Leadership in Oncology

National Comprehensive Cancer Network (NCCN)

23 Sep
NCCN

Immune-oncology
Immunotherapy for Early-Stage Cutaneous Squamous Cell Carcinoma

Immunotherapy for Early-Stage Cutaneous Squamous Cell Carcinoma

AI-Based Histopathology Analysis Predicts Checkpoint Inhibitor Response in Advanced Melanoma

AEGEAN Trial: Durvalumab Reshapes the Tumor Microenvironment in Resectable NSCLC

ARCHER Trial: Prophylactic ALK Resistance Vaccine in Advanced ALK-Positive NSCLC

Spatial Atlas of ADC Targets in Immunotherapy-Treated NSCLC

RP2 First-in-Human Study: Final Results of Oncolytic Immunotherapy in Advanced Solid Tumors

AMBITION Trial: Atezolizumab Added to Paclitaxel and Bevacizumab in HR+/HER2− Advanced Breast Cancer

Gastrointestinal-Oncology
IMMUNIB

IMMUNIB Study Uptades: Nivolumab Plus Lenvatinib in Unresectable HCC

REAL TAB: Trastuzumab-Based Therapy Associated With Improved Survival in HER2-Positive Biliary Tract Cancers

mRCAT-III at ASCO 2026: Node-Sparing RT Plus CAPOX and Tislelizumab in MSS Locally Advanced Rectal Cancer

CodeBreaK 300 at ASCO 2026: ctDNA Clearance Evaluated as an Early Response Biomarker in KRAS G12C-Mutated mCRC

HERBOT at ASCO 2026: Trastuzumab, Nivolumab, Gemcitabine, and Cisplatin in HER2-Positive Biliary Tract Cancer

SWOG S2001 at ASCO 2026: Olaparib Plus Pembrolizumab vs Olaparib Maintenance in gBRCA1/2-Mutated mPDAC

ATTRACTION-6 Trial at ASCO 2026: Nivolumab Plus Ipilimumab With Chemotherapy in HER2-Negative Advanced Gastric/GEJ Cancer

Breast-Oncology
FAST-Forward

FAST-Forward 10-Year Results Support 1-Week Breast Radiotherapy As Standard Of Care

Breast Cancer Highlights From ASCO 2026: ADCs, Biomarkers, and Earlier Treatment Strategies Take Center Stage

AMBITION Trial: Adding Atezolizumab To Paclitaxel And Bevacizumab Did Not Significantly Improve PFS In HR+/HER2− Advanced Breast Cancer

ASCENT-03 Shows SG Benefit Across TNBC Biomarker Subgroups

DESTINY-Breast09 Shows Strong 24-Month PFS Benefit With Deep Responses

SENOMAC: Omitting Completion Axillary Dissection Maintains Survival and Reduces Arm Morbidity in Breast Cancer

OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer

Lung-Oncology
Lung Cancer

Plasma Signals May Open A New Era Of Lung Cancer Prevention

Chemoimmunotherapy May Improve Survival Over PD-(L)1 Monotherapy in PD-L1–High Advanced NSCLC

CHRYSALIS-2 Trail at ASCO 2026: Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

HARMONi-6 Trial at ASCO Plenary 2026: Ivonescimab Plus Chemotherapy Improves Overall Survival in Advanced Squamous Non-Small Cell Lung Cancer

LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC

FLAME Shows Strong 23-Month PFS Benefit in EGFRm NSCLC

TRITON Interim Analysis: Tremelimumab Plus Durvalumab And Chemotherapy Shows Early Response Signal In STK11/KEAP1/KRAS-Mutated NSCLC

OncoDaily TV
Oncology's Greatest Threat: A System in Crisis

Oncology’s Greatest Threat: A System in Crisis

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition: Highlights of the event

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition: Highlights of the event

How Desmond Yip Helped Build Cancer Care in the Solomon Islands

How Desmond Yip Helped Build Cancer Care in the Solomon Islands

Gynecological Cancers, Cancer Vaccines & Immunotherapy: Are We Near Elimination?

Gynecological Cancers, Cancer Vaccines & Immunotherapy: Are We Near Elimination?

Annalice Gandini

GI News Updates with Annalice Gandini

Ringing the Bell Is Not the End of the Story, but the Beginning of a New One: Alejandra Méndez

Ringing the Bell Is Not the End of the Story, but the Beginning of a New One: Alejandra Méndez

Episode 15: Global Health Dialogues with Princess Dina and Dr Garo Armen

Episode 15: Global Health Dialogues with Princess Dina and Dr Garo Armen

Hisham Mehanna

What It Takes to Lead in Oncology Prof. Hisham Mehanna on Research, Mentorship & Life Balance

ASCO

ASCO 2026 with OncoDaily: Yvonne Awards, AI in Oncology, Grand Rounds and Live Coverage from Chicago

Lucica Ditiu

Ending Tuberculosis by 2030: Is It Still Possible? | Dr Lucica Ditiu

City-Level Cancer Care: A Missing Piece in the Puzzle?

City-Level Cancer Care: A Missing Piece in the Puzzle?

Empowering Oncologists: Why Survivorship Matters?

Empowering Oncologists: Why Survivorship Matters?

Not To Miss
20 Posts Not To Miss From ASCO 2026: Lung Edition

20 Posts Not To Miss From ASCO 2026: Lung Edition

15 Posts Not To Miss From ASCO 2026: GI Edition

15 Posts Not To Miss From ASCO 2026: GU Edition

36 Posts Not To Miss From 2026 ASCO Week

25 Posts Not To Miss From ASCO 2026 Day 4

30 Posts Not To Miss From ASCO 2026 Day 3

Grand Rounds by OncoDaily: AI in Oncology Edition Highlights

OncoGrants
Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA

Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA

ACOG Foundation 2026 Request for Grant Proposals

ACOG Foundation 2026 Request for Grant Proposals

Clinical Trial Award — DoD OCRP

Clinical Trial Award — DoD OCRP

Ovarian Cancer Academy – Early-Career Investigator Award — DoD OCRP

Ovarian Cancer Academy – Early-Career Investigator Award — DoD OCRP

Investigator-Initiated Research Award — DoD Ovarian Cancer Research Program

Investigator-Initiated Research Award — DoD Ovarian Cancer Research Program

Kids Beating Cancer — John Voight Memorial Leukemia Research Grant

Kids Beating Cancer — John Voight Memorial Leukemia Research Grant

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
CLL-RT

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: The Current Landscape and Future Perspectives

Follicular Lymphoma (FL): From Evolving Biology to Modern Therapeutic Paradigms

Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story

Colorectal Cancer: Epidemiology, Pathogenesis, Diagnosis, and Therapeutic Advances

Cholangiocarcinoma: Latest Risk Factors, Symptoms, Diagnosis, and 2025 Advanced Treatment Options for Bile Duct Cancer

Pheochromocytoma: Causes, Diagnosis, Treatment, and Breakthrough 2025 Advances in Management

CancerWorld

Oncologists
Gabriele Todisco

Gabriele Todisco

Oncologists Location Milan, Italy
Fatma Ben Abid

Fatma Ben Abid

Oncologists Location Rabat, Morocco
Gilberto Lopes

Gilberto Lopes

Oncologists Location Miami, USA
Zainab Shinkafi-Bagudu

Zainab Shinkafi-Bagudu

Oncologists Location Abuja, Nigeria
Ruzanna Papyan

Ruzanna Papyan

Oncologists Location Yerevan, Armenia
Giuseppe Caruso

Giuseppe Caruso

Oncologists Location Milan, Italy
Fan Daiming

Fan Daiming

Oncologists Location Xi'an, China
Dragana Stanić Tišma

Dragana Stanić Tišma

Oncologists Location Belgrade, Serbia

Oncology Drugs
Sacituzumab Tirumotecan

Sacituzumab Tirumotecan: What Patients Should Know About This Emerging Cancer Treatment

Sacituzumab Tirumotecan: Clinical Development, Mechanism, and Emerging Role in Modern Oncology

Lurbinectedin: What Patients Should Know

Lurbinectedin in Oncology: Mechanism, Clinical Data, Evolving Role, and Future Directions

Bemarituzumab: What Patients with Gastric Cancer Should Know

Bemarituzumab: Uses in Cancer, Side Effects, Dosages, Expectations and More

GSK5764227 (HS-20093): A Novel B7-H3 Targeted Antibody–Drug Conjugate Under Clinical Investigation

OncoDaily Magazine

New Paper Alert
Cardiovascular Disease

Prevention And Management Of Cardiovascular Disease In Adults With Cancer: IC-OS And MASCC Clinical Practice Statement

EORTC–ESTRO

Endpoints in Metastases Directed Therapy for Oligometastatic Cancer A Review and Consensus by the EORTC–ESTRO OligoCare Consortium

MONTBLANC Trial

MONTBLANC Trial Recruitment Completed: Triple Immunotherapy in Advanced HCC

Clinical Trial

How Clinicians Can Truly Understand Clinical Trial Results?

OrigAMI-1 Trial

OrigAMI-1 Trial: Amivantamab in Refractory Metastatic Colorectal Cancer

Drug Discovery

Human-Centric New Approach Methodologies in Drug Discovery

OncoDaily Medical Journal

Hematology

10.69690/ODMJ-001-0526-7344

Analysis of Mortality Factors in the Pediatric Hemato-Oncology Department of the Children's Hospital of Rabat, 2022-2023
Original Research

Radiation Oncology

10.69690/ODMJ-011-0526-7409

An Independent Read-Only Verification and Risk-Management System to Maintain Radiotherapy Safety During Oncology Information System Failure
Case Reports/Brief Reports

Cancer Care

10.69690/ODMJ-001-0426-7451

Distinct differences in the tumour-resident microbiome between early- and late-onset colorectal cancer
Original Research

Hematology

10.69690/odmj-012-0426-7512

Frailty, infections, and bispecific antibodies in multiple myeloma: redefining supportive care in the era of T-cell redirection
Commentaries

Oncology Nursing

10.69690/ODMJ-002-0426-7359

Barriers and Facilitators of Oral Nutritional Supplement Adherence in Cancer: A Systematic Review
Review

Hematology

10.69690/ODMJ-011-0426-7452

Double Dilemma: Managing a Sequential Lymphoma (Case Report)
Case Reports/Brief Reports

Hematology

10.69690/ODMJ-011-0426-7442

Outcome of Hematopoietic Stem Cell Transplantation in Pediatric Patients with Severe Aplastic Anemia and Multi-Drug Resistant Bacterial Infections - A Case Series
Case Reports/Brief Reports

Oncology Nursing

10.69690/ODMJ-001-0404-7332

Enhancing Palliative Care Through Simulation-Based Workshops for Effective Symptom Management
Original Research